Please assess the completion status of the following clinical trial:

Trial Title: TIght COntrol of Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of psoriatic arthritis by a consultant Rheumatologist with less than 24 months disease duration.~* Active disease defined by at least one tender or swollen joint or active enthesitis.~* Age ≥18 years at the time of signing the informed consent form and either male or female patients.~* Patient understands the objectives of the study and is able and willing to sign the Informed Consent Form.~* Men and women of child bearing potential (WCBP) must use at least one adequate birth control measure for the duration of the study and should continue such precautions for 6 months after receiving the last dose of protocol treatment.~* Adequate full blood count within 28 days before randomisation:~  * Haemoglobin count \> 8.5 g/dL~ * White blood count (WBC) \> 3.5 x 10\*9/L~ * Absolute neutrophil count (ANC) \> 1.5 x 10\*9/L~ * Platelet count \> 100 x 10\*9/L~* Adequate hepatobiliary function within 28 days before randomisation:~  \*ALT and/or AST levels must be within 3 times the upper limit of normal range (ULN) for the laboratory conducting the test.~* The patient must be able to adhere to the study visit schedule and other protocol requirements.~Exclusion Criteria:~* Previous treatment for articular disease with disease modifying drugs (DMARDs) including, but not limited to, methotrexate, sulfasalazine, leflunomide,~* Women who are pregnant, lactating or planning pregnancy within 6 months of their last dose of protocol treatment.~* Use of any investigational agents within 4 weeks or within 5 half-lives of the investigational agent, whichever is longer, prior to randomisation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive management (Type: EXPERIMENTAL): None
- Standard management (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).